Raymond James & Associates Argenx Se Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Argenx Se stock. As of the latest transaction made, Raymond James & Associates holds 53,803 shares of ARGX stock, worth $33.8 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
53,803
Previous 55,111
2.37%
Holding current value
$33.8 Million
Previous $23.7 Million
23.12%
% of portfolio
0.02%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding ARGX
# of Institutions
400Shares Held
30.9MCall Options Held
376KPut Options Held
489K-
Price T Rowe Associates Inc Baltimore, MD5.82MShares$3.66 Billion0.36% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.21 Billion2.99% of portfolio
-
Janus Henderson Group PLC London, X02.48MShares$1.56 Billion0.72% of portfolio
-
Capital World Investors Los Angeles, CA1.7MShares$1.07 Billion0.15% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$778 Million10.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $34.8B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...